ESMO: Syros targets KRAS-mutant cancer as CDK7 inhibitor shows early promise

CDK4/6 inhibitors like Pfizer’s Ibrance have changed the treatment of HR-positive, HER2-negative breast cancer. Syros Pharmaceuticals hopes its investigational drug targeting another member of the CDK family could add a new weapon to the treatment arsenal, and it has promising early data in humans and animals to support its plans.